Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561802 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4579301 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL585441 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL31217 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL7523852 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL3468761 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4580141 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL31129 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL875710 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL876407 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145617-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | WASHINGTON UNIVERSITY | 2025-05-08 | — | — | US | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250042925-A1 | Improved Compositions and Methods for Targeting Mitochondria in Cancer Cells | NATIONAL INSTITUTES OF HEALTH | 2025-02-06 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024128829-A1 | TRAP-1 INHIBITOR | 주식회사 스마틴바이오 | 2024-06-20 | — | — | WO | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-0724447-A4 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS INC (US) | 1996-01-22 | — | — | EP | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| US-5236900-A | Treating Candida infections | SCHERING CORPORATION (US) | 1993-08-17 | — | — | US | disclosed |
| WO-1993007883-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0293500-A1 | 3-heteroalkyl-2,4.quinzaoline-diones | AMERICAN CYANAMID COMPANY (US) | 1988-12-07 | — | — | EP | disclosed |
| US-4753944-A | INHIBITING THROMBOXANE SYNTHETASE | AMERICAN CYANAMID COMPANY (US) | 1988-06-28 | — | — | US | disclosed |
| US-4710502-A | THROMBOXANE SYNTHETASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
| US-4684654-A | THROMBOXANE SYNTHETASE INHIBITORS, HYPOTENSIVES | AMERICAN CYANAMID COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | TDP1 473/4885L3MBTL1 1897/4885CHRM2 4463/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | TDP1 4787/4885L3MBTL1 1536/4885CHRM2 514/4885 |
| US-20250042925-A1 | Improved Compositions and Methods for Targeting Mitochondria in Cancer Cells | TFAM, UQCRC2, NDUFAB1 | TDP1 1147/4885L3MBTL1 2743/4885CHRM2 4664/4885 |
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | TDP1 443/4885L3MBTL1 2534/4885CHRM2 4444/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | TDP1 443/4885L3MBTL1 2534/4885CHRM2 4444/4885 |
| US-20250145617-A1 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | SIGMAR1, TMEM97, AIFM2 | TDP1 4797/4885L3MBTL1 2209/4885CHRM2 4248/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | TDP1 4787/4885L3MBTL1 1536/4885CHRM2 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.